The Role of Extracellular Matrix in Cancer Development and Progression

The extracellular matrix (ECM) scaffold, which surrounds and supports the cells in tissues, consists of fibrillar proteins, proteoglycans, glycosaminoglycans, signaling molecules, and enzymes involved in its remodeling. The stages of cancer progression, e.g., local invasion, intravasation, extravasa...

Full description

Saved in:
Bibliographic Details
HerausgeberIn:
Sonstige:
Year of Publication:2022
Language:English
Physical Description:1 electronic resource (182 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 03996nam-a2200841z--4500
001 993545184604498
005 20231214132948.0
006 m o d
007 cr|mn|---annan
008 202205s2022 xx |||||o ||| 0|eng d
035 |a (CKB)5680000000037672 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/81159 
035 |a (EXLCZ)995680000000037672 
041 0 |a eng 
100 1 |a Tzanakakis, George  |4 edt 
245 1 0 |a The Role of Extracellular Matrix in Cancer Development and Progression 
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2022 
300 |a 1 electronic resource (182 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a The extracellular matrix (ECM) scaffold, which surrounds and supports the cells in tissues, consists of fibrillar proteins, proteoglycans, glycosaminoglycans, signaling molecules, and enzymes involved in its remodeling. The stages of cancer progression, e.g., local invasion, intravasation, extravasation, distant invasion and immunosuppression, are obligatorily perpetrated through interactions of these tumor cells with the ECM. Cancer-related ECM changes can be exploited for the evaluation of disease progression, anticancer therapy development, and monitoring of therapy response. Thus, in breast cancer, hyaluronan-mediated wound repair mechanisms are hijacked to promote tumor development. Altered mechanical properties of the pancreatic cancer ECM are immunosuppressive and prevent the penetration of cytotoxic chemotherapy agents. The expression of the proteoglycan syndecan-4 is modulated by anticancer drugs, suggesting its potential druggabilty capacity. Another proteoglycan, lumican, is proposed as a cancer prognosis marker, chemoresistance regulator, and cancer therapy target. Due to their remodeling properties, the MMPs are vital mediators and important therapeutic targets. Treatment of breast cancer cells with sulfated hyaluronan has been shown to attenuate tumor cell growth, migration, and invasion. Extracellular vesicles (EVs), comprising exosomes, microvesicles, and apoptotic bodies, are released by all cells into the ECM and body fluids and can be utilized as diagnostic markers in malignant pleural mesothelioma. These exciting developments encourage tumor biology scientists for further creative research. 
546 |a English 
650 7 |a Research & information: general  |2 bicssc 
653 |a elastin 
653 |a ribosomal protein SA 
653 |a tongue carcinoma 
653 |a MMP-2 
653 |a EGCG 
653 |a pancreatic ductal adenocarcinoma 
653 |a syndecans 
653 |a proteoglycans 
653 |a tumor progression 
653 |a angiogenesis 
653 |a syndecan-4 
653 |a heparan sulfate 
653 |a cancer 
653 |a prognosis 
653 |a biomarker 
653 |a signal transduction 
653 |a proteoglycan 
653 |a metastasis 
653 |a extracellular matrix 
653 |a fibrosis 
653 |a immune cell modulation 
653 |a neutrophils 
653 |a neutrophil extracellular trap 
653 |a macrophages 
653 |a BCC 
653 |a MMP 
653 |a TIMP 
653 |a invasion 
653 |a lumican 
653 |a cancer cell growth 
653 |a motility 
653 |a hyaluronan 
653 |a RHAMM 
653 |a CD44 
653 |a wound repair 
653 |a breast cancer 
653 |a malignant pleural mesothelioma 
653 |a pleural effusion 
653 |a extracellular vesicles 
653 |a biomarkers 
653 |a sulfated hyaluronan 
653 |a estrogen receptors 
653 |a epithelial-to-mesenchymal transition 
653 |a matrix metalloproteinases 
776 |z 3-0365-3405-9 
776 |z 3-0365-3406-7 
700 1 |a Nikitovic, Dragana  |4 edt 
700 1 |a Tzanakakis, George  |4 oth 
700 1 |a Nikitovic, Dragana  |4 oth 
906 |a BOOK 
ADM |b 2023-12-15 05:38:08 Europe/Vienna  |f system  |c marc21  |a 2022-05-14 21:41:54 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337837900004498&Force_direct=true  |Z 5337837900004498  |b Available  |8 5337837900004498